Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.31 USD | -1.77% | +0.53% | -11.27% |
05-14 | Oppenheimer Lowers UroGen Pharma Price Target to $32 From $34, Maintains Outperform Rating | MT |
05-13 | Transcript : UroGen Pharma Ltd., Q1 2024 Earnings Call, May 13, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.27% | 481M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- URGN Stock
- News UroGen Pharma Ltd.
- UroGen Pharma Ltd. Provides Revenue Guidance for the Year 2021